furostanol-i and Breast-Neoplasms

furostanol-i has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for furostanol-i and Breast-Neoplasms

ArticleYear
In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer.
    PloS one, 2023, Volume: 18, Issue:2

    Women's breast cancer is one of the most significant healthcare issues for the human race that demands a proactive strategy for a cure. In this study, the cytotoxic activity (MTT assay) of two natural steroidal compounds, protodioscin and dioscin, against two major subtypes of human breast cancer estrogen receptor-positive (ER-positive)/MCF-7 and triple-negative breast cancer (TNBC)/MDA-MB-468), was assessed. The clonogenic capacity was evaluated using the clonogenic assay. Oxidative stress was determined by measuring the formation of malondialdehyde and H2O2 and the assessment of total antioxidant enzyme activities (SOD, GPx, GR, and TrxR). Protodioscin and dioscin were highly cytotoxic against the tested cell lines (1.53 μM

    Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Female; Humans; Hydrogen Peroxide; Leukocytes, Mononuclear; Triple Negative Breast Neoplasms

2023